Quest Diagnostics (NYSE:DGX) Updates FY 2025 Earnings Guidance

Quest Diagnostics (NYSE:DGX) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 9.550-9.800 for the period, compared to the consensus estimate of 9.720. The company issued revenue guidance of $10.7 billion-$10.9 billion, compared to the consensus revenue estimate of $10.7 billion.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Mizuho increased their target price on shares of Quest Diagnostics from $160.00 to $174.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Bank of America lifted their price objective on Quest Diagnostics from $179.00 to $182.00 and gave the company a “buy” rating in a report on Friday, December 13th. Leerink Partnrs raised Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 6th. Baird R W raised shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 23rd. Finally, StockNews.com upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Wednesday. Six investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and an average target price of $172.69.

Quest Diagnostics Stock Performance

NYSE:DGX opened at $164.47 on Friday. The stock’s 50-day moving average is $155.42 and its 200-day moving average is $153.43. Quest Diagnostics has a 1-year low of $123.04 and a 1-year high of $167.08. The company has a current ratio of 1.25, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83. The stock has a market cap of $18.36 billion, a P/E ratio of 22.10, a price-to-earnings-growth ratio of 2.43 and a beta of 0.90.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $2.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.25%. Equities research analysts anticipate that Quest Diagnostics will post 8.9 earnings per share for the current year.

Quest Diagnostics Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, April 21st. Stockholders of record on Monday, April 7th will be paid a $0.80 dividend. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.75. This represents a $3.20 annualized dividend and a dividend yield of 1.95%. Quest Diagnostics’s dividend payout ratio is presently 40.32%.

Insider Transactions at Quest Diagnostics

In related news, CAO Michael J. Deppe sold 18,755 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $154.05, for a total value of $2,889,207.75. Following the transaction, the chief accounting officer now owns 34,941 shares in the company, valued at $5,382,661.05. The trade was a 34.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.79% of the stock is owned by corporate insiders.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.